Acceleron Pharma (XLRN) CEO John Knopf to Retire; Habib Dable to Replace
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Acceleron Pharma Inc. (NASDAQ: XLRN) announced the Company has appointed Habib Dable as President and Chief Executive Officer to succeed current President and CEO John Knopf. Mr. Dable will assume the CEO role effective December 1, 2016.
Mr. Dable joins Acceleron from Bayer AG, where he most recently served as President of Pharmaceuticals for Bayer in the U.S. In this role, he was responsible for several new product launches while managing the Company’s multi-billion dollar portfolio spanning therapeutic areas including hematology, neurology, oncology, women’s health, and cardiovascular disease. He is also a member of the Board of Directors and Health Section Governing Board of the Biotechnology Innovation Organization (BIO).
Mr. Dable began his career at Bayer in 1994 and quickly moved on to hold a number of senior roles in Canada, Japan and the U.S., focusing on strategic planning, sales management, and global product marketing, including successfully leading global product launches. Prior to his role as President of U.S. Pharmaceuticals, Mr. Dable was global head of specialty medicine for Bayer HealthCare Pharmaceuticals.
“With two Phase 3 trials underway and a strong proprietary pipeline, Acceleron is on the cusp of a key inflection point, and is adding critical commercial competencies to its core strength of research and development,” said Francois Nader, MD, MBA, Chairman of Acceleron’s Board of Directors. “Habib is the right person to take Acceleron forward into this next stage of growth as a company, and build on the visionary and entrepreneurial work of John Knopf. Habib brings a diverse skill set and strong track record within the biopharmaceutical industry. He is a strategic thinker with excellent leadership and communications skills that will help Acceleron deliver on our vision of becoming a leading biopharmaceutical company.”
“I am honored to be given the opportunity to join an established team at Acceleron - a company that has proven itself as a highly successful research and development organization,” said Mr. Dable. “I am excited to work with the Acceleron team and with our partner Celgene as we collaborate to fully recognize the value of our innovative portfolio.”
“As a founder and leader at Acceleron, John has been the key driving force behind the Company and its vision. The Board and entire Acceleron team thank John for his critical contribution to the success of Acceleron over the last 13 years,” said Dr. Nader.
“It has been very rewarding to grow Acceleron from just a vision for a company to where we are today with multiple therapeutics in the clinic,” said Dr. Knopf. “Our progress and growth have been extraordinary. I am very proud of our team and excited about the future of Acceleron.”
About Habib Dable
Habib Dable was most recently President of the Pharmaceuticals division in the United States for Bayer, a global enterprise with core competencies in the life science fields of health care and agriculture. In this role, he was responsible for several new product launches while managing the Company’s multi-billion dollar portfolio spanning therapeutic areas including, hematology, neurology, oncology, women’s health, and cardiovascular disease.
Mr. Dable began his career at Bayer in 1994 as a sales representative in Canada, and later moved on to various sales and marketing roles with increasing management responsibility. He served as Head of Strategic Planning at Bayer HealthCare’s office in Osaka, Japan; Director of International Sales and Marketing for Biologics in Research Triangle Park, North Carolina; Vice President and Regional Head of Hematology/Cardiology responsible for the business in Latin America, Canada, Asia Pacific and Japan; Vice President for Ophthalmology heading the global launch team for EYLEA® (aflibercept), the company’s treatment for various retinal diseases; and as Executive Vice President and Global Head of Specialty Medicine for Bayer.
He is also a member of the Board of Directors and Health Section Governing Board of the Biotechnology Innovation Organization (BIO).
Mr. Dable earned a Masters of Business Administration from the University of New Brunswick in Canada, where he also completed his undergraduate study.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ServiceMaster Global Holdings (SERV) CFO to Alan Haughie Retire; Anthony DiLucente to Succeed; Reaffirms FY Guidance
- Eli Lilly (LLY) to Acquire CoLucid Pharmaceuticals (CLCD) for $960M
- Teva Pharma (TEVA) Announces FDA Approval for VANTRELATM ER with Abuse Deterrence Technology
Create E-mail Alert Related CategoriesCorporate News, Hot Mgmt Changes, Management Changes, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!